Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
目的探讨纤溶酶原激活物抑制物-1（PAI- 1）启动子区基因多态性与脑卒中的关系。
Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。
The screening of human tissue plasminogen activator recombinant plasmid showed that the two methods can recognize the positive colones quickly and correctly.
测序结果表明这两种方法能快速，准确地筛选出阳性克隆。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
方法：检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1（PAI-1），观察检测结果。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
目的：观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1（PAI 1）及凝血烷B2（TXB 2 ）的影响。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一，对维持血浆纤溶系统的稳定起重要作用。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
This was accompanied by severe disruption of the blood-brain barrier and an increased rate of intracerebral hemorrhages after tissue plasminogen activator treatment.
这一现象伴随血脑屏障的严重破坏和组织型纤维蛋白溶酶原激活剂治疗后的脑出血率增加。
Objective: to investigate the clinical effectiveness of prolonged low-dose urine plasminogen activator (u-PA) therapy in patients with unstable angina pectoris (UAP).
目的：观察小剂量长疗程尿纤溶酶原激活物(u - PA)治疗不稳定型心绞痛(uap)的临床疗效。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的研究前炎症细胞因子对人胸膜间皮细胞（HPMC）释放纤溶酶原激活物抑制剂（PAI1）的诱导效应。
The PAI-1 obvious correlates with the IS and CP. The increasement of PAI-1 causing reduction of serum plasminogen activator might be a intermediate process of IR and CBI.
脑梗塞血浆PAI-1活性增高与IS及C肽呈正相关，PAI-1活性增高导致血浆纤溶活性降低，可能是IR引起脑梗塞的中间环节。
The purified t-PA has a higher affinity for fibrin than urokinase. In addition, the melanoma plasminogen activator appeared to be immunologically different from urokinase.
纯化的t-PA与尿激酶相比较，发现前者有更高亲和纤维蛋白的能力。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
目的：探讨急性冠脉综合征患者应用阿托伐他汀调脂治疗后对血管内皮舒张功能、血浆纤溶酶原激活物抑制物1及血管内皮素1的影响。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
Objective to explore the relationship between the activity change of tissue type plasminogen activator (TPA) of retinas and retinal edema in retinal ischemia and reperfusion rats.
目的探讨缺血-再灌注对大鼠视网膜分泌组织型纤溶酶原激活物(TPA)的影响及其与视网膜水肿的关系。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
为探讨纤溶酶原激活物抑制因子1（PAI 1）在肾损伤后纤维化中的作用和意义，揭示其发病的分子病理机制。
The results of theoretical analysis indicate that ILLLIT surely can enhance the activity of plasminogen activator, which is advantageous to decreasing the aggregate degree of erythrocyte.
理论分析结果表明，ILLLIT提高了纤维蛋白溶酶原激活素的活性，有利于红细胞聚集指数的下。
Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.
目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化，以及西比灵干预的影响。
These results suggested that proteolytic activities were involved in implantation, some proteinases such as trypsin and plasminogen activator had important functions during trophoblast invasion.
以上结果说明，小鼠胚胎着床过程中胰蛋白酶及纤溶酶原激活因子等水解蛋白酶的活性起着重要作用。
The researchers also found that plasminogen activator inhibitor type 2 (PAI2), a serine-protease inhibitor, inhibited proteolytic truncation of annexin-1 in macrophages infected with M. tuberculosis.
研究者还发现2型纤维蛋白溶酶原激活因子抑制物(PAI2)(一种丝氨酸蛋白酶抑制物)抑制结核杆菌感染的巨噬细胞内的膜联蛋白- 1的蛋白水解作用。
Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).
目的通过对动脉粥样硬化（AS）兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1（PAI-1）表达的研究，探讨PAI-1在AS中的作用。
Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).
目的通过对动脉粥样硬化（AS）兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1（PAI-1）表达的研究，探讨PAI-1在AS中的作用。
应用推荐